197 results
Page 2 of 10
8-K
EX-99.1
batqrcnzxxk
11 Mar 24
Regulation FD Disclosure
5:03pm
8-K
EX-99.1
ko5c5 oo68dml
13 Feb 24
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
4:10pm
8-K
EX-99.1
rdhsqfax05qm1m9
29 Jan 24
Unregistered Sales of Equity Securities
5:15pm
8-K
EX-99.2
s47 pqqwjy399
29 Jan 24
Unregistered Sales of Equity Securities
5:15pm
8-K
EX-99.2
o0uffb d0
14 Dec 23
Plans to report topline data mid-second quarter 2024
4:01pm
8-K
EX-99.1
nj4 ncb1ocxggridz
14 Dec 23
Plans to report topline data mid-second quarter 2024
4:01pm
8-K
EX-99.1
a1jx50h 2p9
13 Nov 23
Rezolute Reports First Quarter Fiscal 2024 Results
4:13pm
8-K
EX-99
e6sant
18 Oct 23
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism
4:30pm
8-K
EX-99
v4h97hctjvx0
13 Oct 23
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
4:47pm
8-K
EX-99.1
5fbteulujtncv1qvtulf
14 Sep 23
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
4:10pm
8-K
EX-99.1
y83 x9of1f5
27 Jun 23
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025
4:06pm
8-K
7gjo3 o4mk9d31h6i
27 Jun 23
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025
4:06pm
8-K
8etidj4z0oi3gpvn
20 Jun 23
Regulation FD Disclosure
6:55am